Active Immunotherapy CEA Vaccine in Patients With Malignancies Expressing CEA
Phase 1
Completed
- Conditions
- Colon CancerLung CancerBreast Cancer
- Interventions
- Biological: AD5 CEA Vaccine
- First Posted Date
- 2010-06-22
- Last Posted Date
- 2013-03-22
- Lead Sponsor
- Etubics Corporation
- Target Recruit Count
- 35
- Registration Number
- NCT01147965
- Locations
- 🇺🇸
Duke Cancer Research Institute, Duke University, Durham, North Carolina, United States
🇺🇸Medical Oncology Associates, PS, Spokane, Washington, United States
© Copyright 2025. All Rights Reserved by MedPath